We have collected information about Oligonucleotide Delivery Review for you. Follow the links to find out details on Oligonucleotide Delivery Review.
https://www.researchgate.net/publication/262075546_Oligonucleotide_delivery_A_patent_review_2010-2013
Oligonucleotide delivery: A patent review (2010-2013) ... The use of peptides alone or in combination with lipids is an expanding field for oligonucleotide delivery. Polymeric platforms are also ...
https://www.sigmaaldrich.com/technical-documents/articles/material-matters/smart-oligonucleotide-delivery.html
On the basis of the PIC formation mode, either type of PICs, i.e., unit PICs or micellar PICs, can be used for delivery of oligonucleotide. We recently demonstrated the strong potential of unit PICs for in vivo systemic oligonucleotide delivery. A long, two-armed PEG-PLys (MW of PEG: 2 × 37 kDa; DP of PLys: ~20) was designed to form 18 nm unit PICs comprised of a single molecule of siRNA or ASO.
https://www.researchgate.net/publication/47555145_Oligonucleotide_delivery_in_cancer_therapy
Oligonucleotide delivery in cancer therapy Article · Literature Review (PDF Available) in Expert Opinion on Drug Delivery 7(11):1263-78 · November 2010 with 104 Reads How we measure 'reads'
https://ng.neurology.org/content/5/2/e323
Apr 01, 2019 · Perhaps the most significant advantage to ASO therapeutics over other small molecule approaches is that acquisition of the target sequence provides immediate knowledge of putative complementary oligonucleotide therapeutics. In this review, we describe the various types of ASOs, how they are used therapeutically, and the present efforts to ...
http://b2blabs.com/2016/06/oligonucleotides-opportunities-pipeline-challenges/
Jun 07, 2016 · Drug Delivery & Toxicology Challenges. Despite advances at the clinical level, effective delivery of oligonucleotides in vivo continues to be challenging, specifically delivering the active oligonucleotide to correct sites within target cells of target tissues.
https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201914751
Jan 29, 2020 · Systemic Brain Delivery of Antisense Oligonucleotides across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier Dr. Hyun Su Min Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, …
https://www.future-science.com/doi/abs/10.4155/fmc.15.144?journalCode=fmc
Oct 29, 2015 · This review will examine further advances in chemistry that are earlier in the pipeline of oligonucleotide drug candidates. Finally, we consider the possible effect of delivery systems that may provide extra footholds to improve the potency and specificity of oligonucleotide drugs.
https://www.optcongress.com/18/Oligonucleotide-Discovery/
Oligonucleotide Discovery and Delivery Advances in the Development and Delivery of Aptamer, Antisense and RNA Therapeutics ... During this presentation, I will discuss the progress in the advancement of RNAi therapeutics and review delivery of RNAi and where the field is going. I will also discuss conjugated delivery of oligonucleotides to the ...
https://onlinelibrary.wiley.com/doi/full/10.1111/pbi.12496
This review explores the application of ODM as a precision genome editing technology, with emphasis on using oligonucleotides to make targeted edits in plasmid, episomal and chromosomal DNA of bacterial, fungal, mammalian and plant systems. ... However, it is difficult to compare different oligonucleotide delivery methods because conversion ...
https://academic.oup.com/nar/article/46/4/1584/4731547
Dec 12, 2017 · GalNAc delivery is now contributing to a wide spectrum of clinical and pre-clinical programs , and is demonstrating sustained efficacy with relatively low doses. The application of GalNAc to the delivery of dsRNAs is an exciting frontier and clinical data will be discussed in detail below.
https://www.oligotherapeutics.org/
Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene ...
https://mct.aacrjournals.org/content/1/5/347
Conceptual simplicity, the possibility of rational design, relatively inexpensive cost, and developments in the sequencing of human genome have led to the use of short fragments of nucleic acid, commonly called oligonucleotides, either as therapeutic agents or as tools to study gene function.
https://www.mdpi.com/2227-9059/6/2/51/pdf
the greatest promise demonstrated for nucleic acid delivery to organs of the body with inherently poor uptake by naked delivery. Examples of some of these CPPs and their applications are listed in Table1 and this review intends to highlight the progress of CPP development for oligonucleotide delivery
http://pqri.org/wp-content/uploads/2017/02/3-SapruPQRI-FDA-Conference-Oligo-2017-Presentation.pdf
CMC Regulatory Considerations for Oligonucleotide Drug Products: FDA Perspective Mohan Sapru, M.S., Ph.D. CMC Lead for Cardiovascular and Renal Products Office of New Drug Products Member, Emerging Technology Team (ETT) Office of Pharmaceutical Quality, CDER, FDA www.fda.gov
https://en.wikipedia.org/wiki/Antisense_therapy
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to cause a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
Searching for Oligonucleotide Delivery Review?
You can just click the links above. The data is collected for you.
